Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention: Primary Results of the STRIVE Trial

被引：0

作者：

Goadsby, P. J. ^{[1
]}

Reuter, U. ^{[2
]}

Bonner, J. ^{[3
]}

Broessner, G. ^{[4
]}

Hallstrom, Y. ^{[5
]}

Zhang, F. ^{[6
]}

Sapra, S. ^{[6
]}

Picard, H. ^{[6
]}

Mikol, D. D. ^{[6
]}

Lenz, R. A. ^{[6
]}

机构：

[1] Kings Coll Hosp London, London, England

[2] Charite, Berlin, Brandenburg, Germany

[3] Mercy Res, St Louis, MO USA

[4] Med Univ Innsbruck, Innsbruck, Austria

[5] Stockholm Neuro Ctr, Stockholms Lan, Sweden

[6] Amgen Inc, Thousand Oaks, CA 91320 USA

来源：

HEADACHE | 2017年 / 57卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

IOR04

引用

页码：128 / 129

页数：2

共 50 条

[21] Efficacy and Safety of AMG 853 in Asthma: Results of a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
Busse, W. W.
Wenzel, S. E.
Meltzer, E. O.
Kerwin, E. M.
Liu, M. C.
Zhang, N.
Chon, Y.
Lin, J.
Lin, S.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2012, 129 (02) : AB202 - AB202
[22] Efficacy of erenumab (AMG 334) in patients with chronic migraine in North America and Europe: Subgroup analysis of a phase 2, randomised, double-blind, placebo-controlled study
Reuter, U.
Brandes, J.
Dolezil, D.
Tepper, S.
Cheng, S.
Leonardi, D.
Lenz, R.
Mikol, D.
EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 548 - 548
[23] A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant for the Preventive Treatment of Migraine
Croop, R.
Lipton, R. B.
Kudrow, D.
Stock, D. A.
Kamen, L.
Conway, C. M.
Stock, E. G.
Coric, V.
Goadsby, P. J.
CEPHALALGIA, 2021, 41 (1_SUPPL) : 28 - 29
[24] A phase 2/3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rimegepant for the preventive treatment of migraine
Croop, R.
Lipton, R. B.
Kudrow, D.
Stock, D. A.
Kamen, L.
Conway, C. M.
Stock, E. G.
Coric, V
Goadsby, P. J.
HEADACHE, 2021, 61 : 98 - 99
[25] A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant for the Preventive Treatment of Migraine
Croop, Robert
Lipton, Richard
Thiry, Alexandra
Kamen, Lisa
Coric, Vlad
Goadsby, Peter
NEUROLOGY, 2021, 96 (15)
[26] A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant for the Preventive Treatment of Migraine
Croop, R.
Lipton, R. B.
Kudrow, D.
Stock, D. A.
Kamen, L.
Conway, C. M.
Stock, E. G.
Coric, V.
Goadsby, P. J.
JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 19 - 19
[27] Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
Tepper, Stewart
Ashina, Messoud
Reuter, Uwe
Brandes, Jan L.
Dolezil, David
Silberstein, Stephen
Winner, Paul
Leonardi, Dean
Mikol, Daniel
Lenz, Robert
LANCET NEUROLOGY, 2017, 16 (06): : 425 - 434
[28] Results of a phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of astodrimer gel for prevention of recurrent bacterial vaginosis
Schwebke, J.
Carter, B.
Waldbaum, A.
Price, C.
Castellarnau, A.
Paull, J.
McCloud, P.
Kinghorn, G.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2019, 221 (06) : 672 - 673
[29] Efficacy of erenumab (AMG 334) in chronic migraine patients with prior prophylactic treatment failure: Subgroup analysis of the phase 2, randomised, double-blind, placebo-controlled study
Ashina, M.
Tepper, S.
Brandes, J.
Reuter, U.
Boudreau, G.
Dolezil, D.
Cheng, S.
Leonardi, D.
Lenz, R.
Mikol, D.
EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 470 - 471
[30] RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF FEVERFEW IN MIGRAINE PREVENTION
MURPHY, JJ
HEPTINSTALL, S
MITCHELL, JRA
LANCET, 1988, 2 (8604): : 189 - 192

← 1 2 3 4 5 →